Halozyme rises after Phase II pancreatic cancer readout

Halozyme Therapeutics Inc. (NASDAQ:HALO) gained $1.92 (18%) to $12.61 after it reported data from the Phase II HALO 202 study of PEGPH20 to treat pancreatic cancer. The candidate met both of the study's primary endpoints, significantly improving progression-free survival (PFS) across both of the study's stages and significantly reducing thromboembolic events during the trial's second stage.

Halozyme's ongoing Phase III HALO 301 trial of PEGPH20 is evaluating PFS and overall survival (OS) as primary endpoints. PEGPH20 is a recombinant human PH20 hyaluronidase enzyme conjugated to polyethylene glycol (PEG)...